CD8A and neoplasm: Bempegaldes (NKTR-214) is a CD122 agonist that achieves pleiotropic immune activation by preferentially activating the IL-2b receptor; it has a sustained signaling effect, can activate and expand specific anti-tumor effector T cells and NK cells directly in the TME, increases PD-1 expression on the surface of CD8+ T immune cells, and facilitates the binding of this protein to a PD-1 inhibitor (65–67).